Day 1: June 19, 2025 
Policy & Advocacy to Support the Implementation of Comprehensive Genomic Profiling for Patients with Metastatic Cancer in Canada 

Conference Day 1 Opening

‍Cassandra Macaulay, B.Sc., MHS, RTNM, Chief Research Officer, CCRAN 
‍

Welcome from CCRAN’s President & CEO

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A., President & CEO, CCRAN   
Dr. Lisa Dickson, Stage IV Colon Cancer Patient; Health Care Provider  
‍

Collective Advocacy Efforts for Equitable & Timely Access to Advanced Biomarker Testing & Results for Metastatic Cancer Patients in Canada

Cassandra Macaulay, B.Sc., MHS, RTNM, Chief Research Officer, CCRAN 
‍

Key Learnings from CCRAN’s 2024 Biomarkers Conference: “Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada”

‍Dr. Sharlene Gill, MD, MPH, MBA, FASCO, Professor of Medicine, UBC; Medical Oncologist, BC Cancer - Vancouver; Medical & Scientific Advisory Board Co-Chair, Colorectal Cancer Resource & Action Network (CCRAN) 
‍

Generating a Cost-Benefit Analysis to Help Support Access to Comprehensive Genomic Profiling (CGP) for Five Metastatic Cancers in Canada: Helping to Ensure CGP Becomes a Standard of Care in Canada!

Eddy Nason, MPhil, B.Sc., Director, Health, Conference Board of Canada
‍

Reacting to the Findings of CCRAN’s Cost-Benefit Analysis Report: The Value of Accessing Comprehensive Genomic Profiling for Cancer Patients in Canada

‍Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A., President & CEO, CCRAN 
Jenn Gordon, Lead Strategic Operations and Engagement, Rethink Breast Cancer 
Maureen Elliott, Senior Manager, Programs and Support, Pancreatic Cancer Canada 
Bukun Adegbembo, M.Sc., Director of Operations, Canadian Breast Cancer Network 
Stefanie Condon-Oldreive, Founder and Director, Craig’s Cause Pancreatic Cancer Society 
Winky Yau, Manager, Medical Affairs, Lung Cancer Canada 
Austin Zimmer, B.Sc., M.Sc., Support Services Manager & Research Coordinator, Prostate Cancer Foundation Canada 
‍

What Can We Learn from Early Adopters of Comprehensive Genomic Profiling?
An International Discussion

Laura Greer, Patient Expert; Senior Vice President and National Practice Lead, Health & Wellness, Burson Canada, Breast Cancer Advocate
Prof. David Thomas, Ph.D., FRACP, Director, UNSW Centre for Molecular Oncology; CSSO, Omico, New South Wales, Australia  
Dr. Gilad W. Vainer, MD, Ph.D., Onco-Proteomics Lab, Pathology Department Head, Hadassah Medical Center, Jerusalem, Israel 
Dr. Razelle Kurzrock, MD, FACP, Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Chair, Precision Oncology, MCW Cancer Center, Wisconsin, USA
‍

The State of Readiness Progress Report 2.0: How Have Canadian Health Systems Improved?

Don Husereau, B.Sc. Pharm, M.Sc., Adjunct Professor of Medicine, University of Ottawa
‍

What Will it Take to Implement Comprehensive Genomic Profiling as a Standard of Care in Canada for the Management of Metastatic Disease in Cancer Patients? 

Cassandra Macaulay, B.Sc., MHS, RTNM, Chief Research Officer, CCRAN
Laura Greer, Patient Expert; Senior Vice President and National Practice Lead, Health & Wellness, Burson Canada; Breast Cancer Advocate 
Dr. Laura Weeks, Ph.D. , Director, Health Technology Assessment, CDA   
Don Husereau, B.Sc. Pharm, M.Sc., Adjunct Professor of Medicine, University of Ottawa 
Dr. Monika Slovinec D’Angelo, Ph.D., Health System and Policy Consultant, Adjunct Professor, University of Ottawa 
Dr. David Stewart, MD, FRCP(C), Medical Oncologist, The Ottawa Hospital - Cancer Centre; Professor of Medicine, University of Ottawa 
Dr. David Cescon, MD, Ph.D., Medical Oncologist & Clinician Scientist, Princess Margaret Cancer Centre; Associate Professor, Department of Medicine, University of Toronto
Dr. Robert Bell, MDCM, M.Sc., FRCSC, FACS, FRCSE (Hon), Former Ontario Deputy Minister of Health; Professor Emeritus, Department of Surgery, University of Toronto
‍

Glance at Day 2. Closing Remarks from CCRAN’s President & CEO

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A., President & CEO, CCRAN
‍

Day 2: June 20, 2025 
The Future of Comprehensive Genomic Profiling
& Precision Medicine in Clinical Practice  

Conference Day 2 Opening

Cassandra Macaulay, B.Sc., MHS, RTNM, Chief Research Officer, CCRAN 
‍

Welcome from CCRAN’s President & CEO

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. , President & CEO, CCRAN 
‍Dr. Christine Qiong Wu, M.Sc., Ph.D., Stage IV Cancer Patient; Professor of Engineering, University of Manitoba
‍

Reviewing the Findings of a National Canadian Clinician Survey: Identifying Current Clinical Utilization & Utility of Comprehensive Genomic Profiling for Patients Diagnosed with Metastatic Cancer Across Multiple Tumour Types

Shalini Gambhir, B.Sc., MRT(T), MHA, Research Officer, CCRAN     
Cassandra Macaulay, B.Sc., MHS, RTNM, Chief Research Officer, CCRAN  
‍

It Starts at the Lab: Towards Establishing National Standards for the Performance, Integration, Coordination and Communication of Biomarker Testing Results 

Dr. Shantanu Banerji, MD, FRCPC, Director of Precision Oncology and Advanced Therapeutics, CancerCare Manitoba
Robby Spring, B.Sc., M.Sc., MHSc , Patient Advocate; Breast Cancer, Luminal B, Stage 1 Survivor
‍Dr. Doha Itani, MD, Associate Professor, Anatomic & Molecular Pathology, Dalhousie University; Division Head, Molecular Diagnostics & Cytogenetics, Saint John Regional Hospital 
Dr. Jason Karamchandani, MD, Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists
Dr. Angela Hyde, MD, FRCPC, Ph.D., Medical Oncologist & Clinician Scientist, NL Health Services 
Dr. Janessa Laskin, MD, Medical Oncologist and Clinical Researcher, BC Cancer
‍

Why Access Comprehensive Genomic Profiling?
The Many Promising Therapeutic Benefits of a Genome-First Approach

Dr. Thejus Jayakrishnan, MD, Medical Oncologist, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Instructor in Medicine, Harvard Medical School  
Matt Reidy, Founder, Genomic Focus; Long-term, Stage 4 Cancer Survivor    
Dr. Michael Raphael, MD, FRCPC, Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre  
Dr. Mita Manna, MD, FRCPC, Medical Oncologist, Saskatoon Cancer Centre; Associate Professor, Department of Oncology, University of Saskatchewan  
Dr. Ravi Ramjeesingh, MD, Ph.D, FRCPC, Medical Oncologist & Assistant Professor, Chair of the HPB Cancer Disease Site Group Halifax, Division of Medical Oncology and Department of Community Health and Epidemiology, Nova Scotia Cancer Centre & Dalhousie University 
Dr. Stephanie Snow, MD, FRCPC, Medical Oncologist, QEII Health Sciences Centre; Professor, Dalhousie University; President, Lung Cancer Canada  
Dr. Shantanu Banerji, B.Sc. (Med), MD, FRCPC, Director, Precision Oncology and Advanced Therapeutics, CancerCare Manitoba
Dr. Laura Hopkins, MD, FRCSC, Gynecologic Oncologist, Saskatchewan Cancer Agency; Professor in the Department of Oncology, University of Saskatchewan’s College of Medicine 

Activating the Immune Response: Exploring Novel Avenues of Immunotherapy

Dr. Michael Raphael, MD, FRCPC, Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre   
‍Nora Woo, B.Sc., Caregiver of Spouse who succumbed to Stage IV Colorectal Cancer; Patient Advocate; Licensed Realtor
Dr. Pamela Ohashi, Ph.D., FRSC, Senior Scientist, Princess Margaret Hospital; Director, Tumor Immunotherapy Program; Professor, Department of Immunology, Faculty of Medicine, University of Toronto 
Dr. Megan Mahoney, Ph.D. Director, Scientific Affairs and Training, BioCanRx

Innovative AI Based Technology in the Management of Metastatic Cancer 

Dr. Yvonne Bombard, Ph.D., Canada Research Chair, Genomics Health Services & Policy; Professor, University of Toronto; Director & Scientist, St. Michael's Hospital; Co-Founder & CEO, Genetics Adviser ‍
Chamundeeswari Srinivasan, MHIA, M.Sc., Caregiver; Patient Advocate; Healthcare Strategist
Dr. Rob Grant, MD, Ph.D., FRCPC, Medical Oncologist, Princess Margaret Cancer Centre, University Health Network
Dr. Omar Khan, MBA, MD, FRCPC, Clinical Assistant Professor, Medical Oncology, University of Calgary
Dr. Trevor Pugh, Ph.D., FACMG, Associate Professor, Department of Medical Biophysics, University of Toronto; Lead, Clinical Genomics Program, Princess Margaret Cancer Centre; Senior Scientist, Princess Margaret Cancer Centre
‍

Coming in ‘Hot’: The Future of Radioligand Therapies in Canada

Dr. David Laidley, MD, M.Sc., FRCPC, Nuclear Medicine Oncologist; Associate Professor, Western University; Nuclear Medicine Residency Program Director; Associate Scientist, Lawson Research Institute 
‍

The Value of Partnerships to Drive Innovation in Health Care Systems    

Gijs van Rooijen, Ph.D., Chief Scientific Officer, Genome Alberta
Étienne Richer, Ph.D., Director of Genomics Programs, Genome Canada
 

Day 2 Closing Remarks and Conference Adjournment

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A., President & CEO, CCRAN 
‍